Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Anteris Technologies has completed a $320 million capital raise, including a $90 million strategic investment from Medtronic. The investment supports the global pivotal PARADIGM trial and advances the commercialization of the DurAVR Transcatheter Heart Valve. Anteris and Medtronic aim to reshape the TAVR market through clinical science and valve design improvements, while maintaining standards for durability, hemodynamics, and long-term patient outcomes.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios